StreetInsider.com News Articles

Form 4 OMEROS CORP For: Jul 22 Filed by: Demopulos Gregory A MD

Fri, 24 Jul 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260724/26814569.html

Form 4 OMEROS CORP For: Jul 22 Filed by: Demopulos Gregory A MD

Fri, 24 Jul 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260724/26814569.html

Form 4 OMEROS CORP For: Jul 22 Filed by: Cancelmo Peter B

Fri, 24 Jul 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260724/26814565.html

Form 4 OMEROS CORP For: Jul 22 Filed by: Cancelmo Peter B

Fri, 24 Jul 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260724/26814565.html

Form 4 OMEROS CORP For: Jul 22 Filed by: Borges David J.

Fri, 24 Jul 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260724/26814564.html

Form 4 OMEROS CORP For: Jul 22 Filed by: Borges David J.

Fri, 24 Jul 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260724/26814564.html

Omeros repurchases $14.5M of convertible senior notes due 2029

Mon, 20 Jul 2026 17:11:25 -0400

Omeros Corporation (NASDAQ: OMER) completed the repurchase of approximately $14.5 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 on July 20, 2026, for a total purchase price of approximately $29.0 million, inclusive of accrued and unpaid interest and all other obligations.

The transaction was executed through privately negotiated agreements with certain noteholders, following the completion of an averaging period. The agreements were initially entered into on July 2, 2026.

Combined with a previously disclosed repurchase of $16.0 million in principal amount of Notes from the same holders, Omeros has repurchased and retired a total of $30.5 million

Omeros repurchases $14.5M of convertible senior notes due 2029

Mon, 20 Jul 2026 17:11:25 -0400

Combined with a previously disclosed repurchase of $16.0 million in principal amount of Notes from the same holders, Omeros has repurchased and retired a total of $30.5 million

Form 8-K OMEROS CORP For: Jul 20

Mon, 20 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26790382.html

Form 8-K OMEROS CORP For: Jul 20

Mon, 20 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26790382.html

Omeros (OMER) call put ratio 1 call to 2.4 put as share price up 4.9%

Tue, 14 Jul 2026 15:48:36 -0400

Omeros (NASDAQ: OMER) 30-day option implied volatility is at 104; compared to its 52-week range of 60 to 265. Call put ratio 1 call to 2.4 put as share price up 4.9%.

Form 8-K OMEROS CORP For: Jul 02

Mon, 06 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26733233.html

Form 8-K OMEROS CORP For: Jul 02

Mon, 06 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26733233.html

Omeros Corp. (OMER) PT Lowered to $33 at H.C. Wainwright

Mon, 29 Jun 2026 07:07:29 -0400

(Updated - June 29, 2026 7:07 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Omeros Corp. (NASDAQ: OMER) to $33.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "OMER’s negative CHMP opinion for YARTEMLEA is disappointing and likely creates a near-term overhang, but we do not view it as thesis-breaking. We are removing the EU opportunity from our model, lowering our exit multiple, and increasing go-forward R&D spend, which takes our price target to $33 from $40; however, the EU removal itself only reduces our valuation by approximately $2/share, with the U.S. YARTEMLEA launch still representing

Omeros Corp. (OMER) PT Lowered to $33 at H.C. Wainwright

Mon, 29 Jun 2026 07:07:29 -0400

(Updated - June 29, 2026 7:07 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Omeros Corp. (NASDAQ: OMER) to $33.00 (from $40.00) while maintaining a Buy rating.

EMA panel issues negative opinion on Omeros narsoplimab application

Fri, 26 Jun 2026 08:30:57 -0400

Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the company's marketing authorization application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

The decision followed an oral explanation meeting at which Omeros presented its position alongside four international experts in hematopoietic cell transplantation. Omeros said it intends to request a re-examination of the CHMP opinion and will seek review by an Ad Hoc Expert Group, an independent panel of external scientific and clinical experts to be convened by the EMA.

Narsoplimab, sold under

EMA panel issues negative opinion on Omeros narsoplimab application

Fri, 26 Jun 2026 08:30:57 -0400

Narsoplimab, sold under

EMA panel issues negative opinion on Omeros narsoplimab application

Fri, 26 Jun 2026 08:30:57 -0400

Narsoplimab, sold under

EMA panel issues negative opinion on Omeros narsoplimab application

Fri, 26 Jun 2026 08:30:57 -0400

Narsoplimab, sold under

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA